ShEEP Request for CytoViva 3D Darkfield Hyperspectral Microscope
ShEEP Request for CytoViva 3D Darkfield Hyperspectral Microscope
批准号:
9906462
负责人:
Rajagopal Ramesh
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2020-09-30
关键词:
3-DimensionalAcuteAlzheimer&aposs DiseaseAntibodiesAreaArthritisAwardBacteriaBacterial InfectionsBindingBiologicalCancer BiologyCancer CenterCellsChronic DiseaseCitiesCommunitiesComputer softwareConsumptionCore FacilityDiagnosisDiseaseDrug Delivery SystemsDrug PrescriptionsEquipmentFamily memberFundingFutureGrantHealth SciencesHealthcare SystemsHepatitisImageImageryIn VitroInflammatory Bowel DiseasesInstitutesInstitutionIntravenousK-Series Research Career ProgramsLabelLeadLeadershipLegal patentMaintenanceMalignant NeoplasmsMeasurementMediatingMetalsMicroscopeMilitary PersonnelMonitorNoiseOklahomaOpticsOralOrganellesOrganismPainPancreatitisPatientsPeer ReviewPharmaceutical PreparationsPhase I Clinical TrialsPost-Traumatic Stress DisordersProcessProtocols documentationQuality of lifeQuantum DotsReproduction sporesResearchResearch ActivityResearch InfrastructureResearch PersonnelResourcesRoleRouteSamplingScientistSheepShipsSignal TransductionSmall Interfering RNASurveysSymptomsSystemTechnologyTherapeuticTimeTissuesTrainingTreatment FailureTreatment outcomeUnited States National Institutes of HealthUniversitiesVeteransVirusVirus DiseasesWalkingWomananimal imagingcancer clinical trialcancer therapycareerclinical translationdesigndrug developmentdrug efficacyexperienceexperimental studyflexibilityhuman diseaseimprovedineffective therapiesinstrumentinstrumentationintraperitonealmennanomedicinenanoparticleoff-patentparticlepathogenplasmid DNAreceptorsoftware systemstooltrafficking
中文摘要
点击翻译按钮获取中文摘要
英文摘要
One of the challenges in areas of drug development and drug delivery for treating various human diseases
is the lack of understanding of the inherent cellular barriers that restrict the drug efficacy. Another challenge
encountered by researchers conducting intracellular trafficking of molecules and their localization in cellular
organelles is in the use of fluorescent labels that distort the study results with negative influence of these labels
on samples. Further, lack of availability of adequate instrumentation restricts investigators from conducting
cutting-edge research at their own institute. As a result they have to ship their materials to
institutions/universities which are time-consuming, expensive, and do not give the investigator to know the
results quickly. Therefore, continuous expansion of research infrastructure by acquiring appropriate
equipment’s will enhance research activities among research investigator and lead to new discoveries.
To override some of these limitations, we are requesting funds to purchase the CytoViva 3D Enhanced
Darkfield Hyperspectral Microscope for enhancing the research conducted by investigators at the Oklahoma
City VA Health Care System. This system offers high signal-to-noise 3D enhanced darkfield optical
hyperspectral imaging specifically designed for imaging of label free particles/molecules in label-free or
fluorescently labeled live cells and ex-vivo tissue matrices. The unique patented technology of the microscope
allows the visualization and monitoring of particles, drugs, biologics, and cells in solution and in translucent
matrices (cells, tissues, organisms). Thus, studies investigating binding of material (drug, nanoparticle, cell-
particle interaction, antibody binding to cell), receptor-mediated binding and entry into cells (nanoparticles,
quantum-dots, virus, bacteria, metals, antibodies) and intracellular localization and trafficking (siRNA, plasmid
DNA, nanoparticles, virus, bacteria, spores) via various intracellular organelles can be determined in vitro and
in ex-vivo tissue explants with label-free imaging and capture images. The system with the requisite computer
software system provides quantitative spectral analysis of biological and non-biological materials imaged. The
protocols can be automated giving the user to ‘walk-away’ from the instrument, and perform other experiments.
Most importantly, neither the Oklahoma City VA Health Care System nor the affiliated University of
Oklahoma Health Sciences Center (OUHSC) has such an instrument that enables high precision
analysis of label-free materials in cells or ex-vivo tissues. Therefore, this is a truly unique and valuable
resource justifying it purchase as a resource for investigators to conduct existing and new areas of research at
the Oklahoma City VA Health Care System. Availability of this equipment will enhance ongoing studies and
establish new areas of research benefitting the men and women serving the military and veterans.
The equipment will be used by six-major users and a number of future VA users who have six VA Merit
grants funded, three senior career scientist awards, and one career development award funded.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineered Nanoformulation for Immune-modulation in Cancer
-
批准号:10719487
-
项目类别:
-
资助金额:$54.31万
-
财政年份:2023
-
负责人:Rajagopal Ramesh
-
依托单位:
Exosomes as carriers of cancer therapeutics
-
批准号:10312645
-
项目类别:
-
资助金额:$57.62万
-
财政年份:2021
-
负责人:Rajagopal Ramesh
-
依托单位:
An improved IL-24 gene-based therapeutic for cancer
-
批准号:10326352
-
项目类别:
-
资助金额:$34.39万
-
财政年份:2019
-
负责人:Rajagopal Ramesh
-
依托单位:
An improved IL-24 gene-based therapeutic for cancer
-
批准号:10544003
-
项目类别:
-
资助金额:$34.39万
-
财政年份:2019
-
负责人:Rajagopal Ramesh
-
依托单位:
Cancer Research Training and Education Coordination
-
批准号:10627028
-
项目类别:
-
资助金额:$14.1万
-
财政年份:2018
-
负责人:Rajagopal Ramesh
-
依托单位:
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance
-
批准号:10051382
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Rajagopal Ramesh
-
依托单位:
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance
-
批准号:9478535
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Rajagopal Ramesh
-
依托单位:
HuR Targeted Nanotherapy for Lung Cancer
-
批准号:8601528
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2013
-
负责人:Rajagopal Ramesh
-
依托单位:
HuR Targeted Nanotherapy for Lung Cancer
-
批准号:8785610
-
项目类别:
-
资助金额:$38.02万
-
财政年份:2013
-
负责人:Rajagopal Ramesh
-
依托单位:
HuR Targeted Nanotherapy for Lung Cancer
-
批准号:8440451
-
项目类别:
-
资助金额:$40.24万
-
财政年份:2013
-
负责人:Rajagopal Ramesh
-
依托单位:
Small Animal Imaging Core
-
批准号:10455519
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2012
-
负责人:Rajagopal Ramesh
-
依托单位:
Small Animal Imaging Core
-
批准号:10219282
-
项目类别:
-
资助金额:$14.61万
-
财政年份:2012
-
负责人:Rajagopal Ramesh
-
依托单位:
Preclinical Development and Testing of Multifunctional Tumor-Targeted Hybrid Nano
-
批准号:7853312
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2009
-
负责人:Rajagopal Ramesh
-
依托单位:
Preclinical Development and Testing of Multifunctional Tumor-Targeted Hybrid Nano
-
批准号:7568525
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2009
-
负责人:Rajagopal Ramesh
-
依托单位:
Preclinical Development and Testing of Multifunctional Tumor-Targeted Hybrid Nano
-
批准号:7767687
-
项目类别:
-
资助金额:$7.62万
-
财政年份:2009
-
负责人:Rajagopal Ramesh
-
依托单位:
Systemic Non-Viral Gene Therapy for Cancer
-
批准号:7642448
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2008
-
负责人:Rajagopal Ramesh
-
依托单位:
Systemic Non-Viral Gene Therapy for Cancer
-
批准号:8054961
-
项目类别:
-
资助金额:$28.39万
-
财政年份:2008
-
负责人:Rajagopal Ramesh
-
依托单位:
Systemic Non-Viral Gene Therapy for Cancer
-
批准号:7800284
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2008
-
负责人:Rajagopal Ramesh
-
依托单位:
Systemic Non-Viral Gene Therapy for Cancer
-
批准号:7530849
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2008
-
负责人:Rajagopal Ramesh
-
依托单位:
Evaluate the antiangiogenic properties of mda-7/IL-24
-
批准号:6822239
-
项目类别:
-
资助金额:$23.92万
-
财政年份:2004
-
负责人:Rajagopal Ramesh
-
依托单位:
海外基金